ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
港股
詳情
本页面由TTMF Limited提供服务
百利天恆
待上市
成交量:
- -
成交額:
- -
市值:
- -
市盈率:
- -
高:
- -
開:
- -
低:
- -
收:
- -
52周最高:
- -
52周最低:
- -
股本:
4.22億
香港流通股本:
4.22億
量比:
- -
換手率:
- -
股息:
- -
股息率:
- -
淨資產收益率:
-19.00%
總資產收益率:
-5.41%
市淨率:
0.00
市盈率(LYR):
- -
市銷率:
0.00
1
开始申购
11/07
2
申購截止
11/12 09:30
3
公布中签
11/13
4
暗盘
12/31 16:15 - 18:30
5
挂牌上市
11/17
總覽
公司
新聞資訊
公告
估值錨點切換:百利天恒iza-bren如何憑一己之力推高全球雙抗ADC的天花板?
格隆汇
·
2小時前
百利天恒(688506.SH)創新藥BL-ARC002注射液獲臨床試驗批准
智通财经
·
03/22
百利天恒披露iza-bren聯合免疫一線治療廣泛期小細胞肺癌研究數據
证券日报
·
03/19
百利天恒:1187.38萬股限售股3月25日解禁
南方财经网
·
03/17
百利天恒回購70萬股 金額2億元
财中社
·
03/12
華夏時報:百利天恒業績變臉 從年賺37億到年虧10.5億
中金财经
·
03/12
聚焦四川上市公司 | 42家上市川企發布2025年業績預告智明達預增4倍領跑,百利天恒由盈轉虧
金融投资网
·
03/09
一年淨賺37億元到鉅虧10億元!百利天恒業績「變臉」,創新藥燒錢模式能撐多久?
华夏时报网
·
03/09
百利天恒:注射用BL-M11D1(CD33-ADC)獲臨床試驗批准
每日经济新闻
·
03/04
百利天恒:注射用BL-M11D1(CD33-ADC)獲臨床試驗批准
南方财经网
·
03/04
藥企2025年「成績單」揭曉,盈利改善跡象顯著
中金财经
·
03/04
真金白銀力挺硬科技,19家科創板公司公告回購進展
界面
·
03/04
百利天恒累計回購54萬股 金額1.61億元
财中社
·
03/03
業績「變臉」的百利天恒:押注港股「補血」解困
市场资讯
·
03/03
虧損超10億,創新藥龍頭百利天恒「闖關」
阿尔法工场研究院
·
03/02
醫藥生物行業跟蹤周報:2026版基藥目錄調整在即 利好擬納入目錄的中藥標的
东吴证券
·
03/01
營收腰斬預虧10億,BD收益退潮百利天恒亟待核心產品造血
蓝鲸财经
·
02/28
虧損超10億!千億創新藥龍頭百利天恒,「闖關」之路還在繼續
市场资讯
·
02/28
百利天恒:2025年歸母淨虧損10.51億元 按年盈轉虧
每日经济新闻
·
02/27
首度全年盈利的百濟神州,與川股百利天恒有一個共同點:都被這些公募基金重倉
金融投资报
·
02/27
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02615/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02615","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恆","latestPrice":0,"timestamp":1774496761527,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"03-26 11:46:01","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.204,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动;\n2、约30.0%或905.2百万港元将用于建立全球供应链,主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金;\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恆","latestPrice":258.37,"timestamp":1774495765000,"preClose":263.12,"halted":0,"volume":892300,"delay":0,"premium":"-100.00"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","floatShares":421508117,"roa":"-5.41%","roe":"-19.00%","lyrEps":0,"shares":421508117,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","psRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.204,"open":0},"@#url:\"https://hktrade.skytigris.com/ipos/general/02615\",,undefined,":{"id":9063,"type":"COMMON","ipoName":"02615-IPO","symbol":"02615","companyName":"百利天恆","market":"HK","currency":"HKD","status":"CANCELLED","underwriter":"高盛(亚洲)有限责任公司","lotSize":100,"minQty":100,"expectedOfferingSize":8634300,"openingDate":1762479000000,"closingDate":1762911000000,"commonClosingDate":1762911000000,"allotmentDate":1762963200000,"listDate":1763308800000,"marginable":true,"latestPrice":389,"minPrice":347.5,"maxPrice":389,"prospectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","allowedQuantities":[100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700],"recommend":false,"isHint":false,"interestStartDate":1762876800000,"interestEndDate":1762876800000,"delayAllocate":false,"isSupportGreyMarket":true,"greyMarketTradeDate":1763108100000,"transactionRate":0.010085,"gstFeeRate":0,"rank":0,"subscribed":false,"signed":false,"financingInfos":[],"financingNotifyEnabled":false,"financingNotifySubscribed":false,"subscriptionMethods":[],"latestClosingDate":1774496761582,"subscribedFinanceRatio":19.93,"subscribedRatio":19.93,"forecastRatio":24.31,"raiseMoney":335900000,"totalMargin":6694640000,"quoteInfoUpdatedAt":1774413216413,"prospectusUpdatedAt":1762928848000,"forecastMarketValue":155220364085.25,"minForecastMarketValue":146474070657.5,"maxForecastMarketValue":163966657513,"sharesOutstanding":421508117,"business":"公司是一家具備早期研發、臨床開發、生產及商業化能力的綜合醫療企業集團。","greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"tradable":false,"showClawback":false},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02615\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622889113","title":"估值錨點切換:百利天恒iza-bren如何憑一己之力推高全球雙抗ADC的天花板?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622889113","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622889113?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 09:10","pubTimestamp":1774487444,"startTime":"0","endTime":"0","summary":"中国医药创新的领跑时代已至,百利天恒正站在潮头,率先拉开平台化估值重构的大幕,更为中国创新药的全球价值重估写下全新标杆。","market":"fut","thumbnail":"https://img2.gelonghui.com/b17e2-af7974ae-2386-45d1-ba16-2971b9a6c446.jpg?guru_height=720&guru_width=1280&guru_size=154189","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b17e2-af7974ae-2386-45d1-ba16-2971b9a6c446.jpg?guru_height=720&guru_width=1280&guru_size=154189"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4186037","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4231","BK0239","688506","02615","91194","BK4080","ADC"],"gpt_icon":0},{"id":"2621371933","title":"百利天恒(688506.SH)創新藥BL-ARC002注射液獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621371933","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621371933?lang=zh_tw&edition=fundamental","pubTime":"2026-03-22 15:41","pubTimestamp":1774165288,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百利天恒(688506.SH)公告,公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新药BL-ARC002注射液的药物临床试验获得批准。公告称,BL-ARC002通过抗体介导的精准靶向递送技术及放射性核素强大的肿瘤杀伤能力,与传统放射性核素偶联药物相比,具有更强的靶点特异性、更高的肿瘤富集性,并有望展现出更好的抗耐药性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BL","91194","02615","BK1161","LU1815336091.USD","BK4023","BK1574","06978","LU0757428866.USD","688506","BK0239"],"gpt_icon":0},{"id":"2620624216","title":"百利天恒披露iza-bren聯合免疫一線治療廣泛期小細胞肺癌研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2620624216","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620624216?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 13:35","pubTimestamp":1773898522,"startTime":"0","endTime":"0","summary":"百利天恒披露iza-bren联合免疫一线治疗广泛期小细胞肺癌研究数据","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677222420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","02615","91194","688506"],"gpt_icon":0},{"id":"2620428282","title":"百利天恒:1187.38萬股限售股3月25日解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2620428282","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620428282?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 17:50","pubTimestamp":1773741038,"startTime":"0","endTime":"0","summary":"南财智讯3月17日电,百利天恒公告,公司向特定对象发行的限售股将于2026年3月25日上市流通,本次解禁股份数量为1187.38万股,占公司总股本的2.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603173674678418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","688506","02615","BK0239"],"gpt_icon":0},{"id":"2618139911","title":"百利天恒回購70萬股 金額2億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618139911","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618139911?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 19:25","pubTimestamp":1773314707,"startTime":"0","endTime":"0","summary":"百利天恒(688506)发布公告,截至2026年3月12日,公司已回购70万股,占总股本的0.17%,实际回购金额为2亿元,回购价格区间为243.44元/股至345.24元/股。2025年前三季度,百利天恒实现收入20.66亿元,归母净利润-4.95亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603123670321391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","688506","BK0239","02615"],"gpt_icon":0},{"id":"2618188071","title":"華夏時報:百利天恒業績變臉 從年賺37億到年虧10.5億","url":"https://stock-news.laohu8.com/highlight/detail?id=2618188071","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618188071?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 14:42","pubTimestamp":1773297724,"startTime":"0","endTime":"0","summary":"中国经济网北京3月12日讯 华夏时报9日报道《一年净赚37亿元到巨亏10亿元!百利天恒业绩“变脸”,创新药烧钱模式能撑多久?》显示,百利天恒 于2026年2月28日发布2025年年度业绩快报公告。公告显示,公司在2025年实现营业总收入25.2亿元,较上年同期的58.23亿元减少56.72%;归属于母公司所有者的净利润为-10.51亿元,较上年同期的37.08亿元大幅转亏,同比减少128.34%。2025年仅前三季度,百利天恒研发费用就高达17.72亿元,同比增长90.23%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/12/20260312157276.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/12/20260312157276.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260312/32062948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","02615","688506","91194"],"gpt_icon":0},{"id":"2618646015","title":"聚焦四川上市公司 | 42家上市川企發布2025年業績預告智明達預增4倍領跑,百利天恒由盈轉虧","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646015","media":"金融投资网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618646015?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 16:36","pubTimestamp":1773045375,"startTime":"0","endTime":"0","summary":"A股上市公司2025年业绩快报还在持续披露中,截至目前,四川省内已有42家上市公司发布了2025年业绩快报。就已发布业绩快报的四川上市公司的情况来看,其业绩呈现喜忧参半的态势。Wind统计数据显示,在已披露业绩快报的四川上市公司中,有21家全年业绩实现同比增长,占披露总数的一半,其余21家的业绩则出现了不同程度的下滑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666101871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","BK0239","02615","688506","688636","BK0214"],"gpt_icon":0},{"id":"2618646523","title":"一年淨賺37億元到鉅虧10億元!百利天恒業績「變臉」,創新藥燒錢模式能撐多久?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646523","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618646523?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 16:23","pubTimestamp":1773044603,"startTime":"0","endTime":"0","summary":"四川百利天恒药业股份有限公司(下称“百利天恒”,股票代码:688506.SH)于2026年2月28日发布2025年年度业绩快报公告。公告显示,公司在2025年实现营业总收入25.2亿元,较上年同期的58.23亿元减少56.72%;归属于母公司所有者的净利润为-10.51亿元,较上年同期的37.08亿元大幅转亏,同比减少128.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603093666088735.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666088735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","06978","159992","BK0239","BK1161","688506","91194","BK1574"],"gpt_icon":0},{"id":"2616531847","title":"百利天恒:注射用BL-M11D1(CD33-ADC)獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616531847","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616531847?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 18:48","pubTimestamp":1772621317,"startTime":"0","endTime":"0","summary":"每经AI快讯,3月4日,百利天恒公告,注射用BL-M11D1(CD33-ADC)收到国家药品监督管理局签发的《药物临床试验批准通知书》(通知书编号:2026LP00546),同意该药开展单药在复发或难治性骨髓增生异常综合征适应症的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603043661879544.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603043661879544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","ADC","91194","BK4023","BK4231","02615","BL","LU1815336091.USD","LU0757428866.USD","BK0239","BK4080"],"gpt_icon":0},{"id":"2616531828","title":"百利天恒:注射用BL-M11D1(CD33-ADC)獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616531828","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616531828?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 18:46","pubTimestamp":1772621164,"startTime":"0","endTime":"0","summary":"南财智讯3月4日电,百利天恒公告,注射用BL-M11D1(CD33-ADC)收到国家药品监督管理局签发的《药物临床试验批准通知书》(通知书编号:2026LP00546),同意该药开展单药在复发或难治性骨髓增生异常综合征适应症的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603043661879085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","BK4080","LU1815336091.USD","91194","02615","BK0239","BK4231","BK4023","ADC","LU0757428866.USD","BL"],"gpt_icon":0},{"id":"2616533748","title":"藥企2025年「成績單」揭曉,盈利改善跡象顯著","url":"https://stock-news.laohu8.com/highlight/detail?id=2616533748","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616533748?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 17:19","pubTimestamp":1772615990,"startTime":"0","endTime":"0","summary":"近期,赛诺医疗、百济神州、迪哲医药等上市药企陆续交出了2025年的“成绩单”。盈利改善迹象显著部分药企以惊人的增长速度向市场证明了自身的成长韧性。2025年,公司实现归属于母公司所有者的净利润4728.63万元,较上年同期激增3057.05%。此外,还有百济神州作为科创板创新药龙头,在2025年交出了一份高分答卷。复旦张江2025年营业总收入为6.86亿元,同比减少3.33%;归母净利润约亏损1.57亿元,同比下降496.23%。2025年,公司归母净利润达1.59亿元,同比大幅增长406.47%。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/04/20260304142267.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/04/20260304142267.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260304/32044539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02615"],"gpt_icon":0},{"id":"2616070233","title":"真金白銀力挺硬科技,19家科創板公司公告回購進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2616070233","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616070233?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 11:27","pubTimestamp":1772594876,"startTime":"0","endTime":"0","summary":"3月3日晚间,包括澜起科技、百利天恒等19家科创板公司公告回购进展,通过加大回购力度增强投资者回报。同时,多家科创板公司再融资消息不断,路维光电向特定对象发行A股股票申请获上交所受理,先锋精科公告拟发行可转债募资不超过7.5亿元。(界面新闻记者 孙艺真)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304112756a6a033c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304112756a6a033c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02615","BK1163","06809"],"gpt_icon":0},{"id":"2616834626","title":"百利天恒累計回購54萬股 金額1.61億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616834626","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616834626?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 18:32","pubTimestamp":1772533937,"startTime":"0","endTime":"0","summary":"3月3日,百利天恒(688506)发布公告,截至2026年2月28日,公司累计回购54万股,占总股本的0.13%,回购资金总额为1.61亿元,实际回购价格区间为267.36元/股至345.24元/股。2025年前三季度,百利天恒实现收入20.66亿元,归母净利润-4.95亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603033660497540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","02615","688506","BK0239"],"gpt_icon":0},{"id":"2616127783","title":"業績「變臉」的百利天恒:押注港股「補血」解困","url":"https://stock-news.laohu8.com/highlight/detail?id=2616127783","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616127783?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 16:21","pubTimestamp":1772526060,"startTime":"0","endTime":"0","summary":"然而,业绩高光仅维持一年,2025年公司便陷入营收“腰斩”、净利润由盈转亏的困境,核心原因直指合作收入大幅缩水与研发投入持续加码。 证券之星注意到,与业绩大起大落相伴的,是百利天恒一波三折的H股IPO之路。2025年通过港交所聆讯后却因“现行市况”为由暂停上市。资金重压下,2026年公司决议延长H股上市相关决议有效期,继续冲击H股“补血”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-03-03/doc-inhpsxzi4071269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91194","VT","BK4585","BK0239","688506","BK4588","02615","VXUS"],"gpt_icon":0},{"id":"2616368317","title":"虧損超10億,創新藥龍頭百利天恒「闖關」","url":"https://stock-news.laohu8.com/highlight/detail?id=2616368317","media":"阿尔法工场研究院","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616368317?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 19:29","pubTimestamp":1772450940,"startTime":"0","endTime":"0","summary":"2月27日,一则亏损的业绩快报,将“创新药明星股”百利天恒推向了风口浪尖。实际上,尽管市场对百利天恒“成为世界级MNC”寄予厚望,但从目前来看,这条道路并不平坦。在那个创新药尚未成为主流的时代,百利天恒选择布局创新药赛道,无异于一场“豪赌”。2025年,百利天恒达成相关里程碑。截至2025年三季度末,百利天恒研发费用高达17.72亿元,而货币资金仅60.86亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5MzAzNzE0MQ==&mid=2651601354&idx=3&sn=7e3c0a9ee38ed52d0415eb0c4faffa88&chksm=bc11917cd3a78bd741a60cdbcc0d58aa92f438cf0656c058ae27547862a91244224dafdf5ab1&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["06978","159992","BK0239","BK1161","688506","BK1574","02615","91194"],"gpt_icon":0},{"id":"2616271808","title":"醫藥生物行業跟蹤周報:2026版基藥目錄調整在即 利好擬納入目錄的中藥標的","url":"https://stock-news.laohu8.com/highlight/detail?id=2616271808","media":"东吴证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616271808?lang=zh_tw&edition=fundamental","pubTime":"2026-03-01 00:00","pubTimestamp":1772294400,"startTime":"0","endTime":"0","summary":"基药目录调整在即,看好中药板块行情,重点关注济川药业、以岭药业、方盛制药、盘龙药业等。我们认为,基药目录距离上一轮调整已经8 年,此次新版《国家基本药物目录管理办法》的发布,为新版基药目录的出台提供了明确的指导办法,基药目录调整有了实质性的进展。此外,历史情况表明,中药品种纳入基药目录后,放量趋势明确,基药目录落地,有望提振板块整体业绩。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260301184710a72d554e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260301184710a72d554e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252152.HKD","BK1161","LU2543165471.USD","02615","02359","09606","HK0000252160.HKD","HK0000500386.USD"],"gpt_icon":0},{"id":"2614162788","title":"營收腰斬預虧10億,BD收益退潮百利天恒亟待核心產品造血","url":"https://stock-news.laohu8.com/highlight/detail?id=2614162788","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614162788?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 18:23","pubTimestamp":1772274236,"startTime":"0","endTime":"0","summary":"不过,根据其2025年业绩快报,百利天恒又重回亏损状态。以上影响因素导致公司2025年营业收入,利润总额,归属于母公司所有者的净利润,归属于母公司所有者的扣除非经常性损益的净利润同比减少。2025年11月12日,A股已上市的创新药企百利天恒公告称,鉴于目前市场情况,公司决定延迟H股的全球发售及上市。也有业内人士分析,此次百利天恒延迟H股上市的核心原因是其定价策略与目前市场环境错配有关。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1772274125940328845","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["02615","91194","688506"],"gpt_icon":0},{"id":"2614899570","title":"虧損超10億!千億創新藥龍頭百利天恒,「闖關」之路還在繼續","url":"https://stock-news.laohu8.com/highlight/detail?id=2614899570","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614899570?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 09:42","pubTimestamp":1772242920,"startTime":"0","endTime":"0","summary":" 创新药的BD阶段已过,业绩兑现将成为未来药企的主流方向。 2月27日,一则亏损的业绩快报,将“创新药明星股”百利天恒推向了风口浪尖。 业绩快报显示,2025年度公司实现营收25.2亿元,同比减少56.72%;净亏损10.51亿元,同比扩大128.34%。业绩“过山车”背后,核心原因在于百利天恒尚未拥有核心稳定的药品,缺乏“自主造血”能力。 实际上,尽管市场对百利天恒“成为世界级MNC”寄予厚望,但从目前来看,这条道路并不平坦。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-28/doc-inhpirys0140297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","688506","BK1161","91194","06978","02615","BK0239","BK1574"],"gpt_icon":0},{"id":"2614799835","title":"百利天恒:2025年歸母淨虧損10.51億元 按年盈轉虧","url":"https://stock-news.laohu8.com/highlight/detail?id=2614799835","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614799835?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 17:19","pubTimestamp":1772183985,"startTime":"0","endTime":"0","summary":"每经AI快讯,2月27日,百利天恒(688506.SH)发布2025年年度业绩快报,营业总收入为25.20亿元,同比减少56.72%;归属于母公司所有者的净利润为-10.51亿元,同比盈转亏。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602273656760446.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656760446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","688506","BK0239","02615"],"gpt_icon":0},{"id":"2614083875","title":"首度全年盈利的百濟神州,與川股百利天恒有一個共同點:都被這些公募基金重倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083875","media":"金融投资报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614083875?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 16:51","pubTimestamp":1772182279,"startTime":"0","endTime":"0","summary":"金融投资报记者贺梦璐“盈利了,但市值却跌破3000亿元。”这或许是百济神州发布2025年度业绩快报后,留给资本市场的最大困惑。金融投资报记者注意到,当投资者将目光转向其股东名单时,一个有意思的巧合开始浮现:那些重仓百济神州的公募基金,同样也对川股百利天恒青睐有加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656715059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","BK4585","BK1161","91194","BK4588","BK0239","02615","LU0588546209.SGD","BK1583","BK1588","LU1770034418.SGD","688506","688235","LU0307460666.USD","ONC","LU1719994722.HKD","BK4139","BK4526","BK1500","LU1251922891.USD","06160","LU1303224171.USD","LU1969619763.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":179,"code":"91000000","status":"200"}]}}